51 results
6-K
EX-10.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Current report (foreign)
5:28pm
any Subsidiary is in default with respect to any Indebtedness.
(ff)Tax Status. Except for matters that would not, individually or in the aggregate … federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
-6
RISK FACTORS
S-7
USE OF PROCEEDS
S-10
DIVIDEND POLICY
S-11
CAPITALIZATION
S-12
CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS
S-14
PLAN … tax purposes for any taxable year, which could subject United States investors in the ordinary shares to significant adverse United States income tax
6-K
EX-99.2
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Jan 24
Current report (foreign)
7:43am
and a modification of certain existing grants in April 2023.
Income tax expense
There was no income tax expense for the six months ended September 30, 2023
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Jan 24
Current report (foreign)
7:43am
Loss before income taxes
Income tax (benefit) expense
Net loss attributable to non-controlling interest
Net loss attributable to Virax stockholders … . As of September 30, 2023, all of the Company’s outstanding warrants are equity-classified warrants. See Note 14.
Income tax
The income tax expense or credit
424B3
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
20 Dec 23
Prospectus supplement
4:03pm
, tax or legal services or any other
expenses that they incur in disposing of the Ordinary Shares. We will bear all other costs, fees and expenses … by the selling stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholders in disposing
F-3
7d0i1
5 Dec 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
j9jr5s
8 Nov 23
Current report (foreign)
4:11pm
6-K
EX-99.3
hateeysvj7m wck
8 Nov 23
Current report (foreign)
4:11pm
6-K
EX-4.1
2rt wnn2ub
12 Oct 23
Current report (foreign)
8:00am
6-K
EX-10.1
e295x350
1 Sep 23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
7:37am
424B3
7t2ba3d9l58 1pgovlx
31 Mar 23
Prospectus supplement
4:04pm
424B3
2m23bpus735ljniidek
2 Dec 22
Prospectus supplement
4:17pm
F-1
s6oxred9c6e
18 Nov 22
Registration statement (foreign)
5:39pm
6-K
EX-10.3
acrslirppxb7w355s9
8 Nov 22
Virax Biolabs Group Limited Announces $3.8 Million Private Placement
4:56pm
6-K
EX-10.4
y345kbpy2v14c5qeqyt
8 Nov 22
Virax Biolabs Group Limited Announces $3.8 Million Private Placement
4:56pm
6-K
EX-10.1
w9b97kq87rfvd5sk7z
8 Nov 22
Virax Biolabs Group Limited Announces $3.8 Million Private Placement
4:56pm
6-K
EX-10.2
9bp4gq cdv
8 Nov 22
Virax Biolabs Group Limited Announces $3.8 Million Private Placement
4:56pm